Allergy and Immunology · Allergic Asthma

Precision Medicine: Biologics for Severe Allergic Asthma

At a Glance

Biologics are add-on medicines for severe allergic asthma that stays uncontrolled despite high-dose inhalers and trigger management. Doctors choose among treatments targeting IgE, eosinophils, IL-4 and IL-13, or TSLP using test results and the full clinical picture.

When standard inhalers and pills are not enough to manage severe allergic asthma, doctors look to biologics. These are advanced, precision medications made from living cells that “intercept” the specific immune signals driving your inflammation ^[1].

Biologics are not for everyone; they are reserved as add-on therapy for severe asthma that remains uncontrolled despite high-dose inhalers and the management of triggers ^[2]. To qualify, you will typically need a specialist referral and evidence of frequent flare-ups (exacerbations) or a dependence on oral steroid tablets ^[3]^[4]. Before selecting a biologic, your assessment will verify the asthma diagnosis and review comorbidities, triggers, medication adherence, and inhaler technique to ensure the asthma is truly uncontrolled ^[5].

How Biologics Match Your Phenotype

Doctors select a biologic by looking at your phenotype—the physical and biological characteristics of your asthma ^[6]. They use specific “biomarkers” from blood and breath tests to guide this shared decision, though no single biomarker determines the treatment perfectly:

Targeting Allergic Triggers (Anti-IgE)

Omalizumab: This is the original biologic for allergic asthma. It binds to IgE, the antibody that triggers allergic reactions ^[1]. It is generally used for patients with confirmed allergies to year-round triggers (like dust mites or pets) and a total IgE level within a specific range ^[5]^[7].

Targeting Eosinophils (Anti-IL-5)

If your blood tests show high levels of eosinophils (a type of white blood cell), your asthma may be “eosinophilic” ^[5].

Mepolizumab and Reslizumab: These block IL-5, the “recruiter” protein that tells your body to produce more eosinophils ^[1].
Benralizumab: This targets the receptor on the eosinophil itself, causing the body’s natural killer cells to remove them ^[1].

Targeting the Dual Pathway (Anti-IL-4/IL-13)

Dupilumab: This blocks the signaling of two messengers, IL-4 and IL-13 ^[1]. It is often considered for patients who have both asthma and high levels of FeNO (nitric oxide in the breath), or those who also suffer from nasal polyps or severe eczema ^[8]^[5].

The Upstream Approach (Anti-TSLP)

Tezepelumab: Unlike the others, this blocks a signal called TSLP that is released right at the lining of the lungs ^[9]. Because it works “upstream” before the other signals start, it has been shown to be effective across a broader range of patients, including those with or without high allergic/eosinophilic markers ^[10]^[11].

What to Expect During Treatment

Biologics are administered as an injection under the skin (subcutaneous) or as an infusion through a vein ^[12]. Depending on the product and local regulations, some can be self-injected at home after initial training, while others must be given or observed in a clinic ^[13].

Assessment Timeline: It takes time for these medications to calm the immune system. Clinicians will establish a baseline assessment and usually review your individualized response after a trial period (e.g., several months) ^[14]. Your doctor will monitor outcomes like exacerbation rate, lung function (FEV1), and oral steroid use, and decide whether to continue, switch, or stop the biologic ^[15]^[16]. Keep in mind that blood counts and biomarkers can fluctuate.
Common Side Effects: The most frequent issues are mild, such as injection-site redness, headaches, or a sore throat (nasopharyngitis) ^[12]^[17].
Serious Risks: While rare, severe allergic reactions (anaphylaxis) can occur, particularly with omalizumab and reslizumab ^[18]^[13]. Because of this, initial doses often follow product-label-specific observation guidance, and you must seek urgent care for symptoms of anaphylaxis ^[18].

Choosing the Right Path

There is no “best” biologic; the right choice depends on your specific lab results, age, coexisting conditions, and your lifestyle ^[19]. Biomarkers guide the decision, but they are part of a broader clinical picture. Biologics are an add-on therapy, meaning they do not replace your prescribed inhaled controller treatment unless directed by your specialist ^[6].

Common questions in this guide

What are biologics for severe allergic asthma?

Biologics are prescription medicines made from living cells that target specific immune signals involved in asthma inflammation. They are used as add-on treatment for severe asthma that remains uncontrolled despite high-dose inhaled medicines and trigger management.

How does a doctor choose the right asthma biologic?

The choice is based on your asthma pattern and tests such as blood eosinophils, IgE, and exhaled nitric oxide, also called FeNO. Your flare-ups, oral steroid use, age, other conditions, and preferences also matter, and no single test determines the best medication.

Which biologics target allergic or eosinophilic asthma?

Omalizumab targets IgE and is used for some people with confirmed year-round allergies. Mepolizumab, reslizumab, and benralizumab target the eosinophil pathway, while dupilumab targets IL-4 and IL-13 and tezepelumab targets TSLP.

How are asthma biologics given, and when will I know if they work?

They are given under the skin or through a vein; some can be self-injected at home after training, while others require clinic administration or observation. A specialist usually reviews flare-ups, lung function, and oral steroid use after several months to decide whether to continue, change, or stop treatment.

What side effects and serious reactions can asthma biologics cause?

Common side effects include redness or soreness at the injection site, headache, and sore throat. Rarely, a severe allergic reaction called anaphylaxis can occur, so follow the medication's observation instructions and seek urgent care for signs of a serious reaction.

Can a biologic reduce the need for daily oral steroids?

Some biologics may reduce the need for daily oral corticosteroids in appropriate patients. Any dose reduction must be planned and monitored by your specialist rather than done suddenly on your own.

Will a biologic replace my asthma inhaler?

No. Biologics are add-on treatments and do not replace prescribed inhaled controller medicine unless your asthma specialist tells you to change your regimen.

Get notified when new evidence is published on extrinsic asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Using biomarkers and independent predictors of therapy response to optimize treatment of uncontrolled severe asthma in the biologic era.
Yasui H
Frontiers in allergy 2025; (6()):1719820 doi:10.3389/falgy.2025.1719820.
PMID: 41584312
2
Biologic Therapies for Severe Asthma: Current Insights and Future Directions.
Faria N, Costa MI, Fernandes AL, et al.
Journal of clinical medicine 2025; (14(9)) doi:10.3390/jcm14093153.
PMID: 40364184
3
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
Porsbjerg CM, Menzies-Gow AN, Tran TN, et al.
The journal of allergy and clinical immunology. In practice 2022; (10(5)):1202-1216.e23 doi:10.1016/j.jaip.2021.12.027.
PMID: 34990866
4
Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthma.
Lopez-Rodríguez R, Cañas JA, Mahíllo-Fernández I, Rial MJ
Annals of medicine 2026; (58(1)):2627026 doi:10.1080/07853890.2026.2627026.
PMID: 41672447
5
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
Holguin F, Cardet JC, Chung KF, et al.
The European respiratory journal 2020; (55(1)) doi:10.1183/13993003.00588-2019.
PMID: 31558662
6
Clinical implications of asthma endotypes and phenotypes.
Taunk ST, Cardet JC, Ledford DK
Allergy and asthma proceedings 2022; (43(5)):375-382 doi:10.2500/aap.2022.43.220047.
PMID: 36065106
7
Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A, Brusselle G, Couillard S, et al.
The journal of allergy and clinical immunology. In practice 2024; (12(4)):809-823 doi:10.1016/j.jaip.2024.01.023.
PMID: 38280454
8
Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R, RuiWen Kuo C, Lipworth B
The journal of allergy and clinical immunology. In practice 2020; (8(10)):3363-3370 doi:10.1016/j.jaip.2020.06.048.
PMID: 32673880
9
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Corren J, Pham TH, Garcia Gil E, et al.
Allergy 2022; (77(6)):1786-1796 doi:10.1111/all.15197.
PMID: 34913186
10
The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
Roy P, Rafa ZI, Haque SN, et al.
Cureus 2022; (14(12)):e32156 doi:10.7759/cureus.32156.
PMID: 36601189
11
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, et al.
American journal of respiratory and critical care medicine 2023; (208(1)):13-24 doi:10.1164/rccm.202210-2005OC.
PMID: 37015033
12
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM, Arzenton E, Furci F, et al.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2024; (38(3)):425-448 doi:10.1007/s40259-024-00653-6.
PMID: 38489062
13
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, Zangrilli J, Wechsler ME, et al.
The Lancet. Respiratory medicine 2015; (3(5)):355-66.
PMID: 25736990
14
Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H, Peters JI, Kaur Y, et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019; (123(5)):476-482.e1 doi:10.1016/j.anai.2019.07.026.
PMID: 31382020
15
Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma.
Frix AN, Schleich F, Paulus V, et al.
Biochemical pharmacology 2020; (179()):113944 doi:10.1016/j.bcp.2020.113944.
PMID: 32240649
16
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, et al.
Allergy 2020; (75(5)):1023-1042 doi:10.1111/all.14221.
PMID: 32034960
17
A review of the safety of antibody therapy in severe eosinophilic asthma.
Matera MG, De Novellis V, Rogliani P, Cazzola M
Expert review of respiratory medicine 2026; (20(6)):673-692 doi:10.1080/17476348.2025.2607151.
PMID: 41412959
18
Safety and Efficacy of Dupilumab, Omalizumab, and Mepolizumab in Moderate-to-Severe Asthma: A Systematic Review.
O Omar ZT, Owodeha-Ashaka M, Okobi OE, et al.
Cureus 2025; (17(7)):e88236 doi:10.7759/cureus.88236.
PMID: 40827186
19
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A, Steenkamp J, Singh S, et al.
Journal of medical economics 2022; (25(1)):679-690 doi:10.1080/13696998.2022.2074195.
PMID: 35570578

This page explains biologic options for severe allergic asthma for informational purposes only and does not constitute medical advice. Your asthma specialist can determine whether a biologic is appropriate and advise how to use it safely.

Guide Contents